Expert Opinion on Investigational Drugs

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
CSA, Proquest, Ingenta, Informaworld, Rcgp, and Informahealthcare

  1. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

    Expert Opinion on Investigational Drugs 18(2):189 (2009) PMID 19236265

    Vascular-disrupting strategies impair a tumor's blood vessel network, which is essential for tumor progression and metastasis. Vascular-disrupting agents (VDAs) cause a rapid and selective vascular shutdown in tumors to produce extensive secondary neoplastic cell death due to ischemia. A lead age...
  2. S-1: a promising new oral fluoropyrimidine derivative.

    Expert Opinion on Investigational Drugs 18(3):335 (2009) PMID 19243284

    S-1 is an oral fluoropyrimidine that is designed to improve the antitumor activity of 5-fluorouracil (5-FU) concomitantly with an intent to reduce its toxicity. S-1 consists of tegafur, a prodrug of 5-FU combined with two 5-FU biochemical modulators:5-chloro-2,4-dihydroxypyridine (gimeracil or CD...
  3. Antibacterial drug discovery & development summit.

    Expert Opinion on Investigational Drugs 13(6):715 (2004) PMID 15174958

    Over 100 senior researchers and managers from academic and industrial research organisations attended this 2-day annual international discovery summit on antibacterial R&D. A number of firms, particularly biotechnology firms, presented compounds that are advancing through clinical development. I...
  4. Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials.

    Expert Opinion on Investigational Drugs 13(6):707 (2004) PMID 15174957

    Current international guidelines recommend that the goal of treatment with lipid-lowering therapy in patients with established coronary artery disease (CAD) should be a low-density lipoprotein cholesterol level of < 100 mg/dl. The question that remains to be answered is whether more aggressive l...
  5. Vascular biology support for the use of bevacizumab in colorectal cancer.

    Expert Opinion on Investigational Drugs 13(6):703 (2004) PMID 15174956

    In colorectal cancer, increased expression of the angiogenesis promoter vascular endothelial growth factor correlates with invasiveness, vascular density, metastases, recurrence and prognosis. Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor. In re...
  6. Novel targeted agents in the treatment of lung cancer.

    Expert Opinion on Investigational Drugs 13(6):609 (2004) PMID 15174948

    Lung cancer is the leading cause of cancer-related mortality in the US. Although an improvement in outcome is possible with the continued advancement of cytotoxic-based treatment, clinical research is currently focused on utilising novel molecular targets with proven efficacy in preclinical mode...
  7. Colon cancer angiogenesis and antiangiogenic therapy.

    Expert Opinion on Investigational Drugs 13(6):631 (2004) PMID 15174949

    Metastatic development is the primary cause of cancer treatment failure and is responsible for most deaths from colorectal cancer. For the majority of patients, by the time primary colorectal cancers are diagnosed, sub-clinical or clinically relevant liver metastases have already occurred. The f...
  8. Cataract formation and prevention.

    Expert Opinion on Investigational Drugs 13(6):691 (2004) PMID 15174955

    Cataract, a leading cause of blindness worldwide, is a multifactorial eye disease. In developing countries the incidence of cataract among young generations is not uncommon due to malnutrition, excess exposure to ultraviolet radiation and so on. In developed countries, age-related cataract affec...
  9. Immunotherapeutics for nosocomial infections.

    Expert Opinion on Investigational Drugs 13(6):673 (2004) PMID 15174953

    Nosocomial or hospital-acquired infections are associated with prolonged hospitalisation and increased healthcare costs and resource utilisation. Continued advances in sophisticated medical procedures, an increase in the number of immunocompromised patients and a steady rise in the prevalence of...
  10. The potential of Na+/Ca2+ exchange blockers in the treatment of cardiac disease.

    Expert Opinion on Investigational Drugs 13(6):653 (2004) PMID 15174951

    The Na(+)/Ca(2+) exchanger (NCX), a surface membrane antiporter, is the primary pathway for Ca(2+) efflux from the cardiac cell and a determinant of both the electrical and contractile state of the heart. Enhanced expression of NCX has recently been recognised as one of the molecular mechanisms ...
  11. Molecular biological design of novel antineoplastic therapies.

    Expert Opinion on Investigational Drugs 13(6):577 (2004) PMID 15174947

    Novel therapies represent a new strategy for the development of anticancer agents. New targets derived from the knowledge of the molecular structure and genetic defects has been useful in developing anticancer drugs that prolong or stabilise the progression of tumours with minimal systemic toxic...
  12. Vaccines for the prevention of respiratory viral infections: problems and current status.

    Expert Opinion on Investigational Drugs 13(6):681 (2004) PMID 15174954

    Acute respiratory virus infections cause the majority of lower respiratory tract illnesses and hospitalisations of infants and the elderly. The emergence of new respiratory viruses and a high probability that influenza will cause further pandemics highlights the necessity for developing better p...
  13. Recent advances in natriuretic peptides in congestive heart failure.

    Expert Opinion on Investigational Drugs 13(6):643 (2004) PMID 15174950

    Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these bene...
  14. Novel approaches to antifungal prophylaxis.

    Expert Opinion on Investigational Drugs 13(6):665 (2004) PMID 15174952

    Antifungal prophylaxis represents a significant advance in the management of patients at risk from fungal infections in a variety of settings. Identification of patients at the highest risk and the utilisation of safe and effective drugs maximises the benefits of prophylaxis. Situations in which...
  15. Urotensin-II and the cardiovascular system--the importance of developing modulators.

    Expert Opinion on Investigational Drugs 13(5):479 (2004) PMID 15155123

    Urotensin-II (U-II) potently contracts some large isolated blood vessels and cardiac tissue. However, the maximum effects on human blood vessels and heart are relatively small. U-II dilates human resistance arteries. It markedly decreased myocardial function and increased vascular resistance in ...
  16. Selective activators of thyroid hormone receptors.

    Expert Opinion on Investigational Drugs 13(5):489 (2004) PMID 15155124

    An excess of thyroid hormone (TH) leads to a mix of deleterious (increased heart rate, muscle wasting and osteoporosis) and beneficial effects (reduced serum cholesterol and lipoprotein A and weight loss). All of these actions are mediated by nuclear thyroid hormone receptors (TRs), however, gen...
  17. Effects of ADP-receptor antagonism beyond traditional inhibition of platelet aggregation.

    Expert Opinion on Investigational Drugs 13(5):457 (2004) PMID 15155120

    Atherothrombosis, or thrombus formation, at the site of a disrupted atherosclerotic plaque is the common pathophysiology related to myocardial infarction, ischaemic stroke and peripheral arterial disease. A growing body of evidence demonstrates an important role for vascular inflammation in the ...
  18. Novel pharmacological therapies for the treatment of AIDS-related Kaposi's sarcoma.

    Expert Opinion on Investigational Drugs 13(5):501 (2004) PMID 15155125

    Kaposi's sarcoma (KS) is the most common cancer associated with AIDS. KS aetiology and pathogenesis are still poorly defined and no definitive treatment has yet been identified. However, the introduction in 1996 of highly active antiretroviral therapy as a standard of care for those infected wit...
  19. Efalizumab for psoriasis?

    Expert Opinion on Investigational Drugs 13(5):551 (2004) PMID 15155130

    Psoriasis is a chronic skin disorder characterised by inflammation producing red, thickened areas with a flaky white build-up. Efalizumab is a humanised monoclonal IgG1 antibody that inhibits the binding of T lymphocytes to endothelial cells and their subsequent migration. In patients suffering ...
  20. 2nd International Conference on Immune-Mediated Diseases & 8th International Anti-Inflammation Meeting.

    Expert Opinion on Investigational Drugs 13(5):555 (2004) PMID 15155131